Literature DB >> 2801318

Differential effects of anti-arthritic agents on subnormal plasma iron levels in adjuvant arthritic rats.

K M Connolly1, V J Stecher, P T Speight, R Becker, J Rathman.   

Abstract

Nonsteroidal anti-inflammatory drugs (NSAID's) and other antirheumatic compounds such as disease modifying antirheumatic drugs (DMARD's), immunosuppressives and glucocorticoids were tested to determine if daily medication for two weeks could elevate subnormal levels of plasma iron in adjuvant-arthritic (AA) rats. Aspirin, indomethacin, ibuprofen and phenylbutazone were chosen as representative carboxylic acids and pyrazole NSAID's. Although NSAID's at all doses significantly reduced noninjected paw swelling, no NSAID significantly enhanced subnormal plasma iron levels in AA rats. In contrast, the standard DMARD's auranofin and gold sodium thiomalate, as well as the glucocorticoid, dexamethasone and the immunosuppressives, methotrexate and cyclosporin-A all significantly restored plasma iron levels 28 to 100 percent. Plasma iron depression, a parameter of the acute phase response probably under regulation by pro-inflammatory cytokines, is not reversed by NSAID treatment. This appears to be a useful method for distinguishing NSAID's from other anti-arthritic compounds.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2801318     DOI: 10.1007/bf01972813

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  10 in total

1.  Methotrexate inhibits macrophage activation as well as vascular and cellular inflammatory events in rat adjuvant induced arthritis.

Authors:  W J Johnson; M J DiMartino; P C Meunier; K A Muirhead; N Hanna
Journal:  J Rheumatol       Date:  1988       Impact factor: 4.666

2.  Effect of auranofin on plasma fibronectin, C reactive protein, and albumin levels in arthritic rats.

Authors:  K M Connolly; V J Stecher; D J Pruden
Journal:  Ann Rheum Dis       Date:  1988-06       Impact factor: 19.103

3.  Modulation of the acute phase response and in vitro measurement of interleukin-1 activity following administration of dexamethasone to adjuvant-arthritic rats.

Authors:  K M Connolly; V J Stecher; T LaBrie; C Fluno
Journal:  Immunopharmacology       Date:  1988 May-Jun

4.  Effect of auranofin treatment on aberrant splenic interleukin production in adjuvant arthritic rats.

Authors:  J C Lee; M J Dimartino; B J Votta; N Hanna
Journal:  J Immunol       Date:  1987-11-15       Impact factor: 5.422

5.  Effect of antiarthritic drugs on the enhanced interleukin-1 (IL-1) production by macrophages from adjuvant-induced arthritic (AA) rats.

Authors:  M J DiMartino; W J Johnson; B Votta; N Hanna
Journal:  Agents Actions       Date:  1987-08

6.  Alteration of interleukin-1 activity and the acute phase response in adjuvant arthritic rats treated with disease modifying antirheumatic drugs.

Authors:  K M Connolly; V J Stecher; E Danis; D J Pruden; T LaBrie
Journal:  Agents Actions       Date:  1988-08

7.  Lymphocyte activating factor (LAF) and the acute-phase response in adjuvant arthritic rats.

Authors:  K M Connolly; V J Stecher; S Allin; T LaBrie
Journal:  Exp Mol Pathol       Date:  1988-12       Impact factor: 3.362

8.  Alteration of interleukin-1 production and the acute phase response following medication of adjuvant arthritic rats with cyclosporin-A or methotrexate.

Authors:  K M Connolly; V J Stecher; E Danis; D J Pruden; T LaBrie
Journal:  Int J Immunopharmacol       Date:  1988

9.  Macrophage activation in rat models of inflammation and arthritis. Systemic activation precedes arthritis induction and progression.

Authors:  W J Johnson; K A Muirhead; P C Meunier; B J Votta; T C Schmitt; M J DiMartino; N Hanna
Journal:  Arthritis Rheum       Date:  1986-09

10.  Examination of interleukin-1 activity, the acute phase response, and leukocyte subpopulations in rats with adjuvant-induced arthritis.

Authors:  K M Connolly; V J Stecher; L Kent
Journal:  J Lab Clin Med       Date:  1988-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.